This inventor holds 1 USPTO granted patent. Top assignees: Massachusetts Institute of Technology, The Broad Institute, Inc., The General Hospital Corporation. Active years: 2021.
Company Filing History:
1 out of 8,568 
1 out of 480 
1 out of 3,067 
Years Active: 2021
Title: Thomas Eisenhaure: Innovator in Leukocyte Modulation
Introduction
Thomas Eisenhaure is a prominent inventor based in North Reading, MA (US). He has made significant contributions to the field of genetic research, particularly in the modulation of leukocyte activity. His innovative approach utilizes CRISPR-Cas systems to explore therapeutic applications and modeling mutations in leukocytes.
Latest Patents
Eisenhaure holds a patent titled "Delivery, use and therapeutic applications of the CRISPR-cas systems and compositions for modeling mutations in leukocytes." This invention involves a method for modulating leukocyte activity by delivering a vector containing nucleic acid molecules to a leukocyte. The leukocyte is equipped with Cas9, and the vector expresses one or more RNAs that guide the Cas9 to introduce mutations in target genetic loci. This process modulates the expression of genes within the leukocyte. The invention also identifies genes associated with leukocyte responses and models aberrant leukocyte activation and related diseases. It allows for testing potential treatments, including chemical compounds and gene therapies, to better understand and alleviate leukocyte-associated diseases. Eisenhaure has 1 patent to his name.
Career Highlights
Throughout his career, Thomas Eisenhaure has worked with prestigious institutions, including the Broad Institute, Inc. and the Massachusetts Institute of Technology. His work has significantly advanced the understanding of genetic diseases and therapeutic interventions.
Collaborations
Eisenhaure has collaborated with notable scientists such as Aviv Regev and Oren Parnas, contributing to the advancement of research in his field.
Conclusion
Thomas Eisenhaure's innovative work in leukocyte modulation through CRISPR technology exemplifies the potential of genetic research to address complex diseases. His contributions continue to pave the way for future advancements in therapeutic applications.